Macquarie Sticks to Their Buy Rating for Astellas Pharma (ALPMF)
In a report released today, from Macquarie maintained a Buy rating on Astellas Pharma, with a price target of Yen2,500.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
In addition to Macquarie, Astellas Pharma also received a Buy from TipRanks – DeepSeek’s DeepSeek Drug Manufacturers – General in a report issued yesterday. However, on the same day, TipRanks – OpenAI downgraded Astellas Pharma (Other OTC: ALPMF) to a Hold.
Based on Astellas Pharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of Yen524.32 billion and a net profit of Yen79.21 billion. In comparison, last year the company earned a revenue of Yen462.5 billion and had a net profit of Yen35.91 billion
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.